Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 2, 2004, Pages 410-418

  Sauer, John Michael ^a   Long, Amanda J ^a   Ring, Barbara ^a   Gillespie, Jennifer S ^a   Sanburn, Nathan P ^a   DeSante, Karl A ^a   Petullo, David ^a   VandenBranden, Mark R ^a   Jensen, Charles B ^a   Wrighton, Steven A ^a   Smith, Brian P ^a   Read, Holly A ^a   Witcher, Jennifer W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYATOMOXETINE; ATOMOXETINE; BUFURALOL; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DESIPRAMINE; DICLOFENAC; DRUG METABOLITE; ETHANOLAMINE DERIVATIVE; ISOENZYME; MIDAZOLAM; N NORATOMOXETINE; PHENACETIN; PROPYLAMINE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INTERACTION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE; ENZYMOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYDROXYLATION; LIVER MICROSOME; MALE; METABOLISM; NORMAL HUMAN; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DICLOFENAC; DRUG INTERACTIONS; ETHANOLAMINES; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MIDAZOLAM; PHENACETIN; PROPYLAMINES;

EID: 9144240390     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.058727     Document Type: Article

References (27)

1. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
2. Belle DJ, Ernest S, Sauer JM, Smith BP, Thomasson HR, and Witcher JW (2002) Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 42:1-9.
3. Burke MD and Mayer RT (1983) Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem Biol Interact 45:243-258.
4. Butler MA, Iwasaki M, Guengerich FP, and Kadlubar FF (1989) Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
5. Distlerath LM, Reilly PEB, Martin BP, Davis GG, Wilkinson GR, and Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057-9067.
6. Evans DAP, Maghoub A, Sloan TP, Idle JR, and Smith RL (1980) A family and population study of the genetic polymorphism of the debrisoquine oxidation in a white British population. J Med Genetics 17:102-105.
7. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, and Lemberger L (1985) Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 25:296-301.
8. 3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 157:203-206.
9. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR, ed) pp 473-535, Plenum Press, New York.
10. Leemann T, Transon C, and Dayer P (1992) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
11. Lowry OH, Rosebrough RJ, Farr AL, and Randall RJ (1951) Protein determination with the Folin phenol reagent. J Biol Chem 193:265-275.
12. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
13. Ring BJ, Binkley SN, VandenBranden M, and Wrighton SA (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CPY2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181-186.
14. Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, and Wrighton SA (2001) Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther 297:1044-1050.
15. Ring BJ, Gillespie J, Eckstein JA, and Wrighton SA (2002) Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30:319-323.
16. Sauer JM, Ponsler GD, Long AJ, Mattiuz E, Witcher JW, Thomasson HR, and Desante K (2003) Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 31:98-107.
17. Segel IH (1975) Enzyme Kinetics. John Wiley & Sons, Inc., New York.
18. Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, and Perucca E (1997) Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol 43:315-318.
19. Steiner E, Bertilsson L, Sawe J, Bertling I, and Sjoqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44:431-435.
20. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, and Schuetz EG (1996) Use of human hepatocytes to study P450 gene induction. Methods Enzymol 272:388-401.
21. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
22. van der Hoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomese. J Biol Chem 249:6302-6310.
23. Witcher JW, Long AJ, Sauer JM, Heiligenstein JH, Wilens T, Biederman J, and Spencer T (2003) Atomoxetine pharmacokinetics in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 13:53-64.
24. Wong DT, Threlkeld PG, Best KL, and Bymaster FP (1982) A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61-65.
25. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm Res (NY) 11:921-924.
26. Wrighton SA and Thummel KE (2000) CYP3A, in Metabolic Drug Interactions. (Levy RH, Thummel KE, Trager WF, Hansten PD, and Eichelbaum M eds) pp 115-133, Lippincott Williams & Wilkins, Philadelphia.
27. Yuan R, Flockhart D, and Balian J (1999) Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam and triazolam. J Clin Pharm 39:1109-1125.